We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 21. | 장 마감 후 (AMC) | $-0.55 | — | — | $31.55M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.93 | — | — | $17.64M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-5.86 | — | — | $44.68M |
Consensus PT $19.18 · 11 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Goldman Sachs | — | 의견 유지 | Buy → Buy | — | Goldman Sachs: Buy |
| 2026. 05. 19. | B of A Securities | — | 의견 유지 | Neutral → Neutral | — | B of A Securities: Neutral |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| 보고됨 |
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-4.44 | — | — | $27.98M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 987,351 | $30.08B | 0.05% | — | 신규 편입 |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,525,040 | $25.3B | 0.05% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Stored first · Google News · Yahoo Finance (English)
Investigation launched into Beta Bionics over possible securities law violations after stock plunge. - Pluang
Investigation launched into Beta Bionics over possible securities law violations after stock plunge. Pluang
Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire
Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out GlobeNewswire
Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses - lincolnjournal.com
Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses lincolnjournal.com
BBNX Maintained by Goldman Sachs -- Price Target Lowered to $17. - GuruFocus
BBNX Maintained by Goldman Sachs -- Price Target Lowered to $17. GuruFocus
Goldman Sachs Maintains Beta Bionics(BBNX.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Goldman Sachs Maintains Beta Bionics(BBNX.US) With Buy Rating, Cuts Target Price to $17 Moomoo
Beta Bionics | 4: Statement of changes in beneficial ownership of securities-Director Jones Christy - Moomoo
Beta Bionics | 4: Statement of changes in beneficial ownership of securities-Director Jones Christy Moomoo